Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases

Ann Surg Oncol. 2023 Mar;30(3):1889-1890. doi: 10.1245/s10434-022-12877-3. Epub 2022 Dec 23.

Daryl K A Chia¹, Raghav Sundar^{2

3

4}, Guowei Kim^{1

3

5}, Jia Jun Ang¹, Asim Shabbir^{1

3

5}, Jimmy B Y So^{6

7

8}, Wei Peng Yong^{2

9}

¹ Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore.
² Department of Haematology-Oncology, National University Cancer Institute National University Health System, Singapore, Singapore.
³ Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
⁴ The N.1 Institute for Health, National University of Singapore, Singapore, Singapore.
⁵ Division of Surgical Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore.
⁶ Department of Surgery, University Surgical Cluster, National University Health System, Singapore, Singapore. Jimmy_so@nuhs.edu.sg.
⁷ Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Jimmy_so@nuhs.edu.sg.
⁸ Division of Surgical Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore. Jimmy_so@nuhs.edu.sg.
⁹ Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

No abstract available

Publication types